The new inflammatory drug. Brins Academ has been in development for a number of years. And the studies looking at it, uh, and its effect on bronchiectasis have been going on also for multiple years. So this is a, a well-studied drug in a very large number of patients. Uh, the design of the trials, uh, Compared two doses of Brinziccata, 10 mg per day and 25 mg per day, uh, to placebo. The major findings uh from the, the two studies include diminished frequency of exacerbation and a prolonged duration between exacerbations. Uh, the other major finding, which is, uh, I think, perhaps even more important, was that, uh, in the placebo patients, there was a steady rate of decline in pulmonary function. But in the forensicca group, there was a statistically significant lower decline. In pulmonary function. So the, these results suggest that uh the drug does help preserve uh pulmonary function in bronchiectasis patients, at least over a year's time. Now, as far as symptoms go, we have kind of a broad look uh uh from the patient reported outcome tool, which does suggest patients have improved symptoms taking the drug compared to placebo. But so far, we, we haven't seen more granular information about which symptoms get better. Uh, but it, in the, in the shortest period of time. It, it was found that, uh, in general, uh, the, uh, improvements, uh, came at both the 10 mg per day dose and the 25 mg per day, uh, dose, with one major exception, uh, that, uh, Maintenance of lung function was seen only in the 25 mg per day dose. The other interesting aspect of that is that the side effects profile of the 10 mg per day dose was identical to the 25 mg per day dose. Uh. Personally, I, I don't know of a particular reason to use the 10 mg per day dose over 25 mg per day. Uh, however, it is uh available uh if a clinician feels that it, it has a role.
Presenter
